GLYC Multiplikator Forward P/S GlycoMimetics Inc.

GlycoMimetics, Inc. (GLYC) minimizes capital expenditures by outsourcing production and testing to third-party contractors. This forward P/S trend chart provided by GURU.Markets demonstrates this model, where 1774.30 represents the latest metric reading. However, the firm's stability depends on the success of uproleselan and new investments. Meanwhile, the precision oncology sector remains a defensive asset, independent of global macroeconomic cycles.

GLYC (GlycoMimetics) riwayat Rasio rega marang pendapatan sing dikarepake saka 04.07.2022 nganti 14.02.2025

glycomimetics.com - rincian analitis lan metrik utama (GLYC)

- rega saiki lan proyeksi nilai saham:

Rega saham GlycoMimetics|GLYC - Rentang target analis

- data kapitalisasi pasar:

Kapitalisasi pasar GlycoMimetics, Inc.|GLYC - Total Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham GlycoMimetics|GLYC - Total Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku glycomimetics.com|GLYC - Aset Perusahaan

- data utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

GLYC - Penghasilan resik perusahaan|Bathi sing dikarepake GlycoMimetics, Inc.|GLYC - Nilai perusahaan marang bathi resik|Pangali Forward P/E GlycoMimetics|GLYC - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan GlycoMimetics, Inc.|GLYC - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan GlycoMimetics|GLYC - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan glycomimetics.com|GLYC - Owah-owahan bathi resik saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep GlycoMimetics, Inc.

- rincian pendapatan lan dodolan emiten:

GLYC - Pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan GlycoMimetics|GLYC - Rega marang dodolan|Multiplikator Forward P/S GlycoMimetics, Inc.

Ringkesan analisis perusahaan:GlycoMimetics Corp (GLYC)

For GlycoMimetics, Inc. (GLYC), this indicator serves as a gauge of market confidence in future cash flows amid geopolitical risks to pharmaceutical supply chains. By analyzing the forward EV/Revenue multiple, an investor assesses the ratio of the company's current value to projected sales, which helps identify overpayment for potential income that may be constrained by barriers in patent protection and the execution of global trials.

Perusahaan pesaing

Multiplikator Forward P/S GMAB (Genmab)|Prakiraan rega marang pendapatan Exelixis Inc|Nuvalent Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Kymera Corp|IDYA (IDEAYA Biosciences) - Multiplikator forward rega marang pendapatan|ELVN: Rasio rega marang pendapatan sing dikarepake|ORIC (ORIC Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Relay Therapeutics Inc RLAY|Multiplikator Forward P/S NRIX|Tyra Corp - Kapitalisasi marang prakiraan pendapatan|Verastem, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GLUE|CGEM: Multiplikator forward rega marang pendapatan|Immuneering Corp - Rasio rega marang pendapatan sing dikarepake|CCCC: Multiplikator Forward P/S|Black Diamond Therapeutics, Inc - Rega forward marang dodolan|RPTX (Repare Therapeutics) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep pmvpharma.com PMVP|Rasio rega marang prakiraan pendapatan Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Rega forward marang dodolan|Multiplikator Forward P/S BGMS (Cyclacel Pharmaceuticals)|Multiplikator Forward P/S Aadi Bioscience Inc AADI|ALRN - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan BPMC|SWTX (SpringWorks Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan